Produção Nacional
Revisado por pares
HER2 Status in Gastric and Gastroesophageal Junction Cancer: Results of the Large, Multinational HER-EAGLE Study
2016; Lippincott Williams & Wilkins; Volume: 26; Issue: 4 Linguagem: Inglês
10.1097/pai.0000000000000423
ISSN1541-2016
AutoresWoo Ho Kim, Lourdes Gómez Izquierdo, F Vilardell, Kent‐Man Chu, Geneviève Soucy, Lucas Vieira dos Santos, Geneviève Monges, Giuseppe Viale, María José Brito, Stuart Osborne, Johannes Noé, Xiang Du,
Tópico(s)Colorectal Cancer Treatments and Studies
ResumoHuman epidermal growth factor receptor 2 (HER2) dysregulation is associated with tumorigenesis in gastric/gastroesophageal junction cancer; however, the number of patients with HER2-positive disease is unclear, possibly due to differing scoring criteria/assays. Data are also lacking for early disease. We aimed to assess the HER2-positivity rate using approved testing criteria in a large, real-life multinational population. HER2-positivity was defined as an immunohistochemistry staining score of 3+, or immunohistochemistry 2+ and HER2 amplification detected by in situ hybridization. A total of 4949 patients were enrolled and results showed that 14.2% of 4920 samples with immunohistochemistry results were HER2-positive. HER2-positivity was significantly higher in males (16.1% vs. 9.6% in females), in gastroesophageal versus stomach tumors (22.1% vs. 12.9%), in biopsy versus surgical samples (18.3% vs. 13.0%), in intestinal tumor subtypes versus diffuse (21.5% vs. 4.8%) and mixed types (21.5% vs. 8.5%) ( P <0.001), in mixed versus diffuse types (8.5% vs. 4.8%), and in “other” versus diffuse types (11.7% vs. 4.8%; P =0.002). There were no significant differences between stages. Patients in the youngest age percentile had significantly lower HER2-positivity rates than patients in the remaining percentiles (9.2% vs. 15.9%, 15.7%, and 15.1%; P <0.001). HER2-positivity was highest in France (20.2%) and lowest in Hong Kong (10.4%). In conclusion, HER-EAGLE, the first study of its kind to be conducted in a large, multinational population of almost 5000 patients, gives valuable insights into the real-world HER2-positivity rate in a gastric/gastroesophageal junction cancer patient population not selected for disease stage or histology.
Referência(s)